Skip to main content

EssilorLuxottica acquires the Canadian med-tech start-up Cellview

EssilorLuxottica acquires the Canadian med-tech start-up Cellview

The company’s ultra-widefield proprietary technology allows for fast and easy high-quality images, providing a comprehensive view of the retina

Paris, France (11 February 2025) – Furthering its commitment to elevating industry standards and enhancing the quality of vision care, EssilorLuxottica has acquired Cellview Imaging Inc, a Canadian start-up specialized in innovative diagnostic via retinal imaging. With the company’s proprietary technologies, the Group is building a wider portfolio of ophthalmic instruments and solutions, pursuing its journey into the med-tech space.

Based in Toronto, Cellview designs and manufactures innovative and highly performant diagnostic imaging instruments leveraging solid internal R&D expertise. Currently distributed in North America, Cellview’s solutions allow eyecare practitioners to diagnose retinal pathologies thanks to the ultra-widefield retinal camera capable of capturing significantly larger images compared to most existing technologies. Cellview’s product offering is FDA and CE approved and targets a large market base – from eyecare practices in retail locations to ophthalmology clinics – and is set to be distributed in different geographies, starting with Europe.

Francesco Milleri, Chairman and CEO and Paul du Saillant, Deputy CEO at EssilorLuxottica commented: “We are happy to welcome Cellview’s team to EssilorLuxottica and to work together to accelerate our strategy in vision health. By integrating another pioneering company with strong expertise in R&D and world-class imaging solutions, we will provide a comprehensive portfolio of innovative technologies to the ophthalmic care community to better address the growing need of vision health and the early diagnosis of retinal pathologies. While our products and services remain accessible to all industry players – as a pillar of EssilorLuxottica’s open business model – we continue to elevate market standards, in full alignment with our journey into the med-tech space”.

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.